Pros and Cons of Genus plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 2.340% | 5.645% | 6.504% | -8.392% | -10.884% | -7.224% | -58.740% |
| Ligand Pharmaceuticals | -1.540% | -3.759% | -7.246% | 118.803% | 54.217% | 316.260% | 167.056% |
| United Therapeutics | -1.560% | -3.421% | -5.275% | 86.343% | 5.055% | 103.398% | 189.613% |
| Ionis Pharmaceuticals Inc. | -2.030% | -9.692% | -36.406% | 19.220% | -33.917% | 19.125% | 43.391% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat